The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.

Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.

Experts from The Ohio State University Comprehensive Cancer Center–The James as well as Blanchard Valley Health System discussed the impact of the COVID-19 pandemic on cancer care.

Erin M. Bertino, MD, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer with EGFR mutations and its place among other available EGFR TKIs.

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center–James, discusses the potential impact of the novel coronavirus 2019 (COVID-19) on patients with lung cancer.

David P. Carbone, MD, PhD, director of the Thoracic Oncology Center at The Ohio State University Comprehensive Cancer Center–James, provides perspective on the novel coronavirus 2019 (COVID-19).

Hui-Zi Chen, MD, PhD, discusses how the IMpower133 trial has helped to propel the field of small-cell lung cancer forward.

Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.

David O’Malley, MD, discusses the state of immunotherapy in ovarian cancer.

Larry J. Copeland, MD, discusses the importance of germline testing in ovarian cancer.

Gregory A. Otterson, MD, discusses the utility of immunotherapy in squamous non–small cell lung cancer and targeted the evolution of targeted therapy in biomarker-driven disease.

Hui-Zi Chen, MD, PhD, discusses the use of immunotherapy in ES-SCLC and the work being done to identify mechanisms of resistance to frontline therapy.

Erin M. Bertino, MD, discusses the current treatment landscape and next steps in the EGFR-mutant NSCLC paradigm.

Terence M. Williams, MD, PhD, discusses the impact of the PACIFIC trial on stage III NSCLC and how the hunt for prognostic biomarkers is underway across the lung cancer paradigm.

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.

Clara D. Bloomfield, MD, the 2015 Giants of Cancer® award winner for Myeloid Neoplasms and a revolutionary physician-scientist, died March 1 at the age of 77.

Larry J. Copeland, MD, discusses the prevalence of ovarian cancer in the United States.

John Hays, MD, PhD, discusses immunotherapy research in gynecologic cancer.

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.

Jeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.

Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the use of PARP inhibitors in ovarian cancer.

Jonathan E. Brammer, MD, discusses the role of stem cell transplant in acute lymphoblastic leukemia.

Floor J. Backes, MD, discusses quality of life with PARP inhibitors for patients with ovarian cancer.

Alice S. Mims, MD, discusses her recommendations regarding holding therapy until molecular test results are received for symptomatic patients with acute myeloid leukemia.